Envista Holdings Corporation
NVSTHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Envista Holdings Corporation focuses on Medical Instruments & Supplies services and products. Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company carries a $4.31B market cap, placing it firmly in the mid-cap category. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables.
Market Cap
$4.31B
Beta
0.86
P/E (TTM)
46.22
P/E (Fwd)
16.06
EPS (TTM)
$0.58
EPS (Fwd)
$1.67
ROE
3.1%
ROA
3.2%
Cash
$1.13B
Total Debt
$1.59B
Free CF
$267.9M
52W Change
31.3%
Annual Financials
Cash vs Debt
Where NVST stands vs its 150-day and 200-day moving averages
As of the September 2, 2026 close, NVST finished 1.41% above its 150-day moving average ($26.27) and 5.80% above its 200-day moving average ($25.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is NVST overbought or oversold?
At the September 2, 2026 close, NVST's RSI(14) was 25.3, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Envista Holdings Corporation carries $1.59B in total debt against $1.13B in cash reserves — debt is modestly above the cash position. Managing this leverage effectively will be important for long-term financial stability. Annual free cash flow of $267.9M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. ROE of 3.1% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.2% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $2.57B (2022) to $2.72B (2025).
Investors considering Envista Holdings Corporation should weigh the typical risks associated with NVST's sector, size, and financial profile against their own risk tolerance and investment objectives. No single metric tells the full story. Reviewing NVST's risk profile alongside its fundamentals and technical indicators provides a more complete picture.